1. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
- Author
-
Haggenburg, Sabine, Hofsink, Quincy, Rutten, Caroline E., Nijhof, Inger S., Hazenberg, Mette D., and Goorhuis, Abraham
- Abstract
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.
- Published
- 2022
- Full Text
- View/download PDF